Welcome to the NObreath FeNO Monitor Website

What is FeNO?

FeNO (Fractional exhaled Nitric Oxide) are very miniscule particles of the gas Nitric Oxide (NO), measured in parts per billion. NO is naturally produced by your body to help combat inflammation and when your airway is inflamed, NO is produced in the lungs and exhaled on the breath.

The production of nitric oxide is often found to be higher in inflammatory conditions such as asthma and therefore FeNO monitoring can be used for the detection and management of such conditions2, but also to differentiate between COPD, ACOS other and interstitial lung diseases that are not assessed by other means, such as lung function3.

Airway inflammation is a central process in asthma and other lung diseases1. Being able to detect eosinophilic airway inflammation and monitor a patient’s response to treatment is regarded as a gold standard in the management of respiratory diseases.

Nitric oxide measurement is not intended as a stand-alone method for diagnosis and should be used in conjunction with other evaluation methods and tests4.
Using FeNO measurements to evaluate airway inflammation in asthma represents a significant advance in respiratory medicine5, but until now this has been an expensive test to deliver in everyday practice.

● Non-invasive, quick and easy to perform5
● Shows patient’s response to treatment, enabling the correct prescription of medication and safer/monitored adjustments
● Shows patient compliance
● Aids in identifying patients who do/do not require on-going treatment6
● Shown to be superior to the majority of conventional tests of lung function, such as peak flow recording and spirometry5
● Aids in differentiating between allergic (eosinophillic) and non-allergic asthma7.

FeNO in Asthma

According to asthma UK, approximately 5.4 million people in the UK, receive treatment for asthma9, and approximately 300 million individuals worldwide are thought to be affected by asthma10. It is thought that on average, 3 people die daily from asthma attacks in the UK.9It is thought that the NHS spends approximately £1 billion a year treating and managing asthma symptoms9. Asthma is commonly referred to as an inflammatory disease which affects a person’s airways, leading to hyper-responsiveness, obstruction, mucus hyper-production, and airway wall remodelling10. Although airway eosinophilic inflammation is a key characteristic of asthma, very few methods are available for measuring airway eosinophilic inflammation. Airway eosinophilic inflammation can be measured, by measuring eosinophils and eosinophilic cationic protein (ECP) in sputum, or ECP’s can be measured in a blood sample11. These methods are commonly considered gold standard, but are very time consuming, expensive, and are not commonly readily available.
A majority of asthma patient’s airway inflammation is allergen-driven Th2 response12. There is significant evidence from external literature suggesting FeNO (Nitric oxide) is a key biomarker tool for inflammation of the respiratory tract12. Increased levels of FeNO in asthma are thought to come from inducible NOS2 expressed in the inflamed airways12. NObreath offers an alternative aid to diagnose asthma, which is non-invasive, and significantly more cost effective than current gold standard methods for aiding to diagnose airway eosinophilic inflammation, further aiding in the diagnosis of asthma. As a result of substantial amounts of literature supporting FeNO measurements as an effective biomarker for asthma and other airway inflammation, FeNO breath testing is now recommended in NICE guidelines as an aid to diagnose allergic asthma13. Literature also suggests the ability for FeNO measurement to be used as good management tool for asthma14, assessing the effectiveness of treatments for patients, optimising asthma treatments.

International FeNO use

UK Flag
USA Flag
South Korean Flag
Swiss Flag
Japanese Flag
Portuguese Flag
Czech Flag
Italian Flag
Danish Flag
German Flag
Finnish Flag

NObreath – what is it?

The NObreath is a FeNO monitor which can be used to measure airway inflammation for the management and diagnosis of asthma. Recommended by NICE and conformed to ATS & ERS guidelines, the NObreath makes FeNO monitoring quick, and easy plus it is completely non-invasive, with the ability to monitor airway inflammation in both adult and child patients. Furthermore, the ambient monitoring mode enables you to check ambient levels of NO.
Revolutionary Interface

Full-colour touchscreen with easy-to-use
interfacing and onscreen motivational
exhalation guides

Adult and Child Profiles

Adult & child patient profiles for best
sampling times and quick result referrals

Low Maintenance

Easily serviceable components,
saving time and money

Proven Technology

The NObreath has over 10 years of clinical
use featuring in many studies worldwide

Ergonomic Design

An ergonomic design, fully portable and
incorporated with SteriTouch® technology for
optimum infection control

NObreath Dock

NObreath dock for safe and convenient
storage, charging and synchronisation

No Limits

Subject to correct use, maintenance and service.

As easy as…

Technical Specification


Concentration range


T90 Response time
≤10 seconds


Full-colour touchscreen


Operating temperature


Detection principle
Electrochemical sensor


Storage/transport temperature


Sensor operating life
5 years**


Operating humidity
25-80% RH


Warm-up time
≤60 secs




Rechargeable Li-on battery via USB



Click here to view the entire Tech Specs documentation

*±5ppb of measured value ≤50ppb or ±10% of measured value >50ppb

**Subject to correct use, maintenance & servicing.


Our consumables are made to the highest quality at the most cost effective prices.
NObreath Mouthpiece
The NObreath mouthpiece is single-patient use and has an
integrated infection control filter which removes and traps
>99% of airborne bacteria and >96% of viruses 8.
Monitor Cleaning Wipes
Free from alcohol to ensure continued
performance of your monitor.
Pack of 50 wipes.


We take the utmost pride in the fact that the NObreath is accredited to BS EN ISO13485:2016 and CE marked to the Medical Device Directive (MDD).
New CE mark in black


We’re developing brand new and completely FREE patient management software for the NObreath FeNO monitor and we are pleased to announce the beta version of FeNOchart™ is now available to download here:

Here’s what’s included:

• USB connection to the NObreath
• Create, store, and manage Patient Profiles
• Adult and child breath tests with screen mirroring
• View results in graph format
• Create reports in PDF format
• Embedded NObreath how-to videos
• FeNOchart™ automatically updates on start-up
• GDPR compliant with user logins and accounts
• A firmware update tool for the NObreath

Windows 7 Driver Patch

Download FeNOchart™ Manual:

Please read the FeNOchart manual before using FeNOchart software for the first time.

Download Manual
Image of child blowing into the NObreath FeNO monitor

Last but not least, there are more exciting features to come, including but not limited to:

• Download readings from your NObreath and save them directly to the patient profile
• Ambient NO tests with screen mirroring
• Multiple languages for the software

Worldwide Forum

With the purchase of a NObreath you are eligible to become a member of the NObreath® forum – a place where you can seek answers, offer help or simply discuss FeNO techniques, findings and much more with other healthcare professionals from around the world.
Already own a NObreath?
Click here to sign up today.





Method Comparison Study



FeNO Interpretation chart Icon

FeNO Interpretation Chart

ICMG icon-04

Infection Control
Maintenance Guidelines


User Manual


All the latest on the NObreath and FeNO monitoring…

Where to buy?

We operate through a network of carefully selected distributors worldwide – to find your
nearest distributor, click here

Medical Advisory Board

We work with a network of KOLs in the respiratory world to make sure the NObreath is fit for purpose. We are always working to improve our NObreath if you would like to be a part of this advisory board, please contact Bedfont today.
John Dickinson

Professor at Universidade Brasil, Supervisor of MSc and PhD Program at UNIFESP and Director of IBEPIPE, Rodolfo de Paula Vieira has a PHD in Pathology – specifically the Immunopathology of the lungs – and 3 post-doctoral accreditations from the Sao Paulo, School of Medicine in Brazil, the Department of Pneumology at the University Hospital Freiburg in Germany and a post-doctoral fellowship awarded by European Respiratory Society and Marie Currie Foundation and European Union. Having published more than 100 internationally peer-reviewed scientific articles, Professor Vieira’s main pre and clinical studies evolve around immune response and the effects of physical exercise on pulmonary rehabilitation.

Professor and honorary consultant specialising in campus to clinic research, Dr Dominick Shaw’s main research interest is in severe asthma. He is the Nottingham lead in the largest asthma research consortium to date, the international £20M UBIOPRED EU IMI severe asthma project which is defining a phenotypic handprint in chronic severe asthma. Dr Shaw is also the lead for the commissioned severe asthma service, a past member of the British Thoracic Society’s asthma advisory group, and he also contributed to past BTS/SIGN national asthma guidelines. Currently, Dr Shaw sits on the Asthma and NIHR RfpB UK research boards.

John Dickinson is a BASES (The British Association of Sport and Exercise Sciences) accredited Sport and Exercise Physiologist and his main area of research focuses on respiratory problems in athletes. He has over 10 years’ experience of investigating issues such as asthma and dysfunctional breathing in athletes. John has published extensively in the area of exercise induced asthma and has given key note presentations internationally on the subject. Since 2008, he has been a UK Sport Advisor for asthma diagnosis in elite athletes and has worked alongside many professional football and rugby clubs as well as professional and Olympic athletes.

Our Mission

To help improve asthma diagnosis & management of adults and children worldwide through FeNO monitoring.

Our Purpose

To make FeNO monitoring more accessible globally, with the creation of an effective yet cost-efficient FeNO monitor and equally low cost consumables.

Customer Charter

What we do:

  1. Work hard to design and manufacture the most up to date, high quality, innovative products for use by worldwide health professionals.
  2. Re-invest our profit into future research and development to keep our products up to life saving standards.
  3. Strive to produce high quality consumables at the lowest possible prices.
  4. Are committed to provide a very high level of quality customer service that takes account of the changing needs and expectations of our customers.
  5. Work to continuously improve the quality in all that we do.

The NObreath FeNO monitor is a product from Bedfont Scientific Ltd.

Our family, innovating health, for yours.


LinkedIn Twitter Facebook Instagram Youtube

Bedfont Scientific Ltd., Station Yard, Station Road, Harrietsham, Maidstone, Kent, ME17 1JA, England
© 2020 Bedfont Scientific Ltd., all rights reserved | Privacy Policy | Bedfont Scientific Limited reserves the right to change or update this website without prior notice.
Incorporated in England and Wales under registered number: 1289798
View the Battery Declaration of Conformance


1. Shelhamer JH, Levine SJ, Wu T, Jacoby DB, Kaliner MA, Rennard SI. NIH conference: airway inflammation. Ann Intern Med 1995;123:288-304.
2. Saito J, Gibeon D, Macedo P, Menzies-Gow A, Bhavsar P, Chung K. Domiciliary diurnal variation of exhaled nitric oxide fraction for asthma control. 2017.
3. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005; American Journal of Respiratory and Critical Care Medicine; vol. 171: 912-930;2005
4. Correlation of Exhaled Nitric Oxide, Spirometry and Asthma Symptoms: Journal of Asthma: Vol 42, No 10 [Internet]. Tandfonline.com. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/abs/10.1080/02770900500371344

More References

5. Andrew D. Smith, Jan O. Cowan, Sue Filsell, Chris MacLachlan, Gabrielle Monti Sheehan, Pamela Jackson and D. Robin Taylor. Diagnosing Asthma: Comparisons between Exhaled Nitric Oxide Measurements and Conventional Tests. Am J Respir Crit Care Med Vol 169. pp 473-478, 2004.
6. D R Taylor, MW Pinenburg, A D Smith and J C D Jongste. Exhaled nitric oxide measurements: clinical application and interpretation. Thorax 2006;61:817-827.
7. Coumou HBel E. Improving the diagnosis of eosinophilic asthma [Internet]. Taylor and Francis online. 2017 [cited 15 March 2017]. Available from: http://www.tandfonline.com/doi/full/10.1080/17476348.2017.1236688
8. Public Health England. An Evaluation of Filtration Efficiencies Against Bacterial and Viral Aerosol Challenges Report No. 18/040. London: Public Health England; 2019.

More References

9. Asthma facts and statistics | Asthma UK [Internet]. Asthma UK. 2019 [cited 2 December 2019]. Available from: https://www.asthma.org.uk/about/media/facts-and-statistics/
10. Kudo M, Ishigatsubo Y, Aoki I. Pathology of asthma. Frontiers in Microbiology. 2013;.
11. PIZZICHINI E, PIZZICHINI M, EFTHIMIADIS A, DOLOVICH J, HARGREAVE F. Measuring airway inflammation in asthma: Eosinophils and eosinophilic cationic protein in induced sputum compared with peripheral blood. Journal of Allergy and Clinical Immunology. 1997;99(4):539-544.
12. Keller A, Rodriguez D, Russo M. Nitric oxide paradox in asthma. Memórias do Instituto Oswaldo Cruz. 2005;100(suppl 1):19-23.
13. Asthma – NICE CKS [Internet]. Cks.nice.org.uk. 2019 [cited 2 December 2019]. Available from: <a href=”https://cks.nice.org.uk/asthma#!diagnosisSub” title=”click for more information”>https://cks.nice.org.uk/asthma#!diagnosisSub</a>
14.Ricciardolo F, Sorbello V, Ciprandi G. FeNO as biomarker for asthma phenotyping and management. Allergy and Asthma Proceedings. 2015;36(1):88-88.


For more information on Bedfont's stance on Coronavirus and breath testing, please click the button below.